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I. INTRODUCTION 
 
Follicular lymphoma (FL) is the most prevalent form of indolent B-cell 
lymphomas, accounting for up to 20-35% of all non-Hodgkin lymphomas, and is 
recognized as a distinct entity in the World Health Organization (WHO) 
Classification of lymphoid tumours. Based on the proportion of centroblasts 
within the malignant follicles, FL are divided into grade 1 (predominantly 
centrocytes), grade 2 (centrocytes and centroblasts) grade 3A (predominantly 
centroblasts, but centrocytes are still present) and grade 3B (solid sheets of 
centroblasts) categories. Approximately 85-90% of FL carry the 
t(14;18)(q32;q21) chromosomal translocation, juxtaposing the BCL2 gene with 
the immunoglobulin heavy chain (IgH) gene, resulting in the constitutive 
expression of BCL2 protein, which induces prolonged cell survival by blocking 
programmed cell death. FL is considered to derive from the germinal centre 
(GC) B-cells, based on the immunophenotype of tumour cells, accumulation of 
somatic hypermutation (SHM) in their immunoglobulin (Ig) genes and 
expression of activation-induced cytidine deaminase (AID) required for SHM.  
Approximately 10-15% of FL are negative for BCL2 protein, and 5% 
do not exhibit the t(14;18) chromosomal translocation either. Several reports 
suggest that FL without translocation and expression of BCL2 gene have distinct 
morphological, genetic and molecular characteristics that distinguish them from 
the BCL2-positive FL. These BCL2-negative FL frequently are grade 3 FL, 
however BCL2-negative cases were also observed in lower grade groups. 
Furthermore, the grade 3B FL frequently harbour translocation of the BCL6 
gene, carry trisomy of chromosome 3, and gain of chromosome 18 or 18q. It is 
currently unclear whether this lymphoma derives from GC or post-GC B-cells.  
 
 
 
 
Based on the immunophenotype (CD10
-
, MUM1
+
) and frequent BCL6 gene 
rearrangement, it has been suggested that these BCL2-negative FL may have a 
“late-stage GC” or “post-GC” cell origin, and are probably more closely related 
to the diffuse large B-cell lymphomas (DLBCL).  
 Somatic hypermutation (SHM) targets primarily the immunoglobulin 
variable region genes in the germinal centre. This process introduces single 
nucleotide substitutions, with rare deletions and duplications, resulting in the 
production of high-affinity antibodies and allowing affinity-maturation of the 
humoral immune response.  
Genetic instability plays an important role in the development and 
progression of human tumours. Aberrant somatic hypermutation (ASHM) 
is a recently identified form of genetic instability, regarded as a malfunction of 
the physiological SHM mechanism. The aberrant activity of the SHM process 
affects multiple loci outside the physiological target genes, including, proto-
oncogenes BCL2, BCL6, c-MYC, PAX-5, RhoH and PIM1. Thus, ASHM 
represents a novel and powerful mechanism of malignant transformation.  
SHM has been shown to malfunction in about 50% of DLBCL, in BCL2-
positive-FL, in mediastinal large B-cell lymphoma, in about 20% of AIDS-
related NHL, in primary central nervous system DLBCL, in primary cutaneous 
marginal zone B-cell lymphoma and MALT lymphoma. ASHM has also been 
associated with FL and CLL transformation into higher grade DLBCL. 
However, ASHM in BCL2-negative FL has not been described.   
Activation-induced cytidine deaminase (AID) plays an essential role in 
the process of SHM and class-switch recombination (CSR). As a result of AID 
activity the conversion of deoxy-citidine (dC) to deoxy-uridine (dU) occurs, 
leading   to  formation  of   guanine-uracil  mismatches  in  the  DNA   molecule.  
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Depending on the type of the specific repair mechanisms activated in order to 
resolve these mismatches, different types of somatic point mutations or double 
stranded DNA breaks could take place.  
 In healthy B-cell development the expression of AID is strictly 
regulated and restricted to GC B-cells (SHM and CSR), which follows that 
constitutive expression of AID may contribute to NHL formation by generating 
genome-wide genetic instability through mutations and illegitimate DNA 
recombinations. This is also supported by previous findings indicating that AID 
is overexpressed in BCL2-positive FL, DLBCL, Burkitt lymphoma, mediastinal 
large B-cell lymphoma and MALT lymphoma. AID expression in BCL2-
negative FL has not yet been described.   
 
 
 
 
 
 
 
 
 
 
.  
 
 
 
 
 
 
 
 
II. OBJECTIVES 
 
 
Several reports suggest that FL without translocation and expression of 
BCL2 gene have distinct morphological, genetic and molecular characteristics 
that distinguish them from the BCL2-positive FL.  
 
 
 We characterized the mutational pattern of IgVH genes to 
provide further insight into the molecular pathways of 
lymphomagenesis and to reveal the cellular origin of FL 
without BCL2 involvement. 
 
 We analysed whether c-MYC, PAX-5 and RhoH proto-
oncogenes are differently affected by aberrant somatic 
hypermutation (ASHM) in BCL2-negative FL in comparison 
with BCL2-positive FL. 
 
 We determined the mRNA and protein expression level of 
activation-induced (cytidine) deaminase (AID) in BCL2-
negative FL compared to BCL2-positive FL. 
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III. MATERIALS AND METHODS 
 
III. 1. Histological samples 
 
  Lymph node (LN) biopsies of 18 patients with FL were selected for 
this study, based on the availability of frozen tissue for molecular analyses and 
formalin-fixed paraffin-embedded tissue for immunophenotyping and 
fluorescence in situ hybridization (FISH) analysis. Diagnoses were based on 
histopathology, immunophenotype, FISH and molecular analyses, and cases 
were classified according to the World Health Organization (WHO) 
Classification of lymphoid tumours. Peripheral blood samples from 8 healthy 
individuals and GC cells microdissected from 5 reactive follicles were used as 
controls for this study. 
 
III. 2. DNA based analyses 
 
DNA was extracted from 18 fresh frozen lymph node samples of cases 
of FL and specific gene regions were amplified. To characterize the SHM 
activity on IgVH genes PCR amplicons were first cloned, then the appropriate 
insert of plasmid DNA was sequenced, while in case of c-MYC, PAX-5 and 
RhoH genes direct sequencing was used to determine the ASHM mutational 
activity. The sequence analysis was performed using the IMGT/V-QUEST 
(International imMunoGeneTics information System, http://imgt.cines.fr) and 
the NCBI (National Centre for Biotechnology Information) GenBank databases. 
  
III. 3. RNA based analyses 
 
  In   order  to  determine  the  expression  level  of   activation-induced  
 
 
 
cytidine deaminase (AID) mRNA total RNAs were isolated from fresh frozen 
lymph nodes of eight cases of BCL2-negative FL and seven cases of BCL2-
positive FL. Germinal centre (GC) cells obtained by laser microdissection from 
5 reactive lymph nodes were also subjects of RNA isolation and used as positive 
controls. Furthermore, RNAs of mononuclear cells from peripheral blood (PB) 
of eight healthy volunteers were used as negative controls. The expression level 
of AID was determined after reverse transcription by quantitative real-time PCR 
assay (Q-RT-PCR) using the CT method.  
 
III. 4. Protein based analyses 
 
 To support our results on protein level, we carried out 
immunohistochemistry on all 18 FL samples. Immunohistochemistry was 
carried out using biotin-free conjugated polymer system. Images were taken 
using digital microscopy. 
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IV. RESULTS 
 
IV. 1. Sequence analysis of IgVH genes 
 
PCR analysis resulted amplification in 13 cases; in 5 samples (cases 3, 
4, 8, 13 and 18) IgVH gene mutations were not analysed due to unsuccessful 
amplification. The closest germline VH gene, as well as the sequence homology 
and mutational frequency of IgVH genes were defined. To determine whether the 
tumour cells of FL had been under pressure for antigen selection, we analysed 
the somatic mutations of all IgVH sequences amplified. In all analysed sequences 
the Chang and Casali binomial distribution model revealed more R mutations in 
the CDRs, and in most cases fewer R mutations in the FRs than could be 
expected due to chance alone, with significant (p<0.05) clustering.  The results 
obtained by the multinomial model suggested by Lossos et al. revealed 
statistically significant p values, except in one case. Taken together, our results 
indicate the presence of antigen selection in these clones. 
 
IV. 2. Mutational analysis of c-MYC, PAX-5 and RhoH genes 
 
Eight cases of BCL2-negative FL and seven cases of BCL2-positive FL 
were subjected to mutational analysis. The obtained sequences in case of c-MYC 
exon 1 and exon 2, PAX-5 and RhoH genes were compared to the corresponding 
germline gene sequences available in the NCBI GenBank database and 
corresponding positions were used to localize mutations. Previously reported 
polymorphisms and mutations appearing more than once in separate cases, thus 
considered as polymorphic variants, were excluded from further analyses. 
Totally 7 mutations were found in BCL2-positive FL and 7 mutations in BCL2- 
 
 
 
negative FL. The mutation pattern introduced by ASHM corresponds to the 
specific features of the SHM process seen in physiologic targets. Mutation 
distribution was similar in the examined two groups: single nucleotide 
substitutions predominated, with only a few insertions and no deletion. There 
was an equal distribution of transitions (C>T, T>C, G>A) and transversions 
(T>A, A>T, C>G, G>C, C>A). The ratio of G+C over A+ T substitution was 
elevated: 5/1 for BCL2-positive FL and 3/2 in case of BCL2-negative FL. A 
preferential distribution within the RGYW motif (R=A/G, Y=C/T, W=A/T) was 
observed only in 1 out of 6 single bp substitutions in cases of BCL2-positive FL 
and in 3 out of 5 mutations in cases of BCL2-negative FL. 
 
IV. 3. Analysis of AID mRNA expression 
 
 To compare the AID expression of BCL2-negative and positive FL, we 
measured the levels of expression of AID mRNA in 15 cases of FL (8 BCL2-
negative and 7 BCL2-positive), germinal centre B-cells and peripheral blood 
(PB) mononuclear cells by quantitative real-time PCR assay. These results were 
calculated as the mean of three independent measurements using the 
comparative CT method (ΔΔCT). The levels of AID mRNA were defined as a 
ratio of AID to β-actin expression. Mononuclear cells from peripheral blood of 
eight healthy volunteers were used as negative controls and as expected a low 
AID expression was detected. In GC cells, used as positive controls, the 
measured AID expression level was high. The difference between the average 
level of relative expression values of follicular lymphoma without and with the 
presence of BCL2 was statistically not significant (p>0.05).  
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IV. 4. Analysis of AID protein expression 
 
AID protein levels were also detected in all 18 FL cases from formalin-
fixed paraffin-embedded tissue samples. There was no significant difference 
between the protein expression values of follicular lymphoma with and without 
the presence of BCL2. The AID protein was predominantly localized in the 
cytoplasm of germinal centre B-cells. No correlation was observed between AID 
mRNA and protein expression levels. Furthermore, no correlation has been 
found between FL grade, the presence or absence of BCL2 protein and AID 
expression. Similarly, there was no correlation between AID mRNA and protein 
expression levels and ASHM mutations in the c-MYC, PAX-5 and RhoH genes. 
However, due to the relative small number of examined cases we were not able 
to make major conclusions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V. DISCUSSION 
 
The t(14;18) translocation and BCL2 overexpression are believed to be 
strongly associated with the development of FL, hence, the absence of these 
abnormalities in B-cell neoplasms may point to a substantially different 
transformational pathway and a separate entity.  
To characterize a possible homogenous subtype of FL in which 
overexpression of BCL2 gene is not involved, we selected FL cases showing 
neither the t(14;18) translocation nor the expression of BCL2 protein. The GC 
origin of these lymphomas was supported by a follicular growth pattern, the 
BCL6 and CD10 (except in 2 cases) expression of the tumour cells, and by the 
presence of CD21 and CD23-positive follicular dendritic reticulum cells within 
the neoplastic follicles. Morphological analysis of these BCL2-negative FL 
showed two cases of grade 2 and nine cases of grade 3A FL; there were no cases 
of grade 3B FL. In our series, only three out of 11 BCL2-negative samples 
showed BCL6 gene alterations, in contrast with previous reports, in which a 
significant fraction of FL without t(14;18) translocation harboured alterations of 
the BCL6 gene. BCL6 alterations were also observed in one BCL2-positive FL 
from the control group. 
The SHM process of Ig genes is a characteristic feature of FL. IgVH 
sequence analysis of FL lacking BCL2 translocation and expression revealed 
ongoing somatic mutations generating intraclonal heterogeneity of the tumour 
clones. The average mutational frequency within the IgVH region of FL cases 
without BCL2 gene rearrangement and expression was 12.76% (range 2.41% to 
28.62%) which is similar to the average 11.9% frequency (range 9.79% to 
16.12%) found in FL harbouring the t(14;18) translocation. The pattern and 
distribution of  these mutations  were highly  consistent with antigen selection as  
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calculated by the binomial and the multinomial distribution models. Taken 
together, these results indicate that cases of FL without BCL2 gene 
rearrangement and expression are derived from GC B-cells, and this subtype of 
FL is not distinct from FL carrying t(14;18) translocation based on the 
mutational pattern of IgVH. 
According to a widely accepted recent hypothesis a multistep model of 
tumourgenesis is instrumental in the pathogenesis of FL. The initiating genetic 
event is the translocation of t(14;18), causing constitutive expression of the anti-
apoptotic BCL2, but antigenic stimulation and signalling through the antigen 
receptor is required for the neoplastic transformation. Using protein microarray 
analysis Zha et al. showed that BCL-XL or AKT/BAD pathways may provide an 
alternative anti-apoptotic signal in FL in the absence of BCL2 protein, and our 
study may provide evidence that GC microenvironment and antigenic selection 
are also instrumental in the development of BCL2-negative FL. Our data suggest 
that BCL2-positive and BCL2-negative FL may have different molecular 
alterations at the starting point of lymphomagenesis, but in both cases the 
immunoglobulin receptor complex may provide additional signal(s) required for 
malignant transformation. 
SHM occurs during the centroblast stage of B-cell maturation and 
requires the presence of AID. AID is highly expressed in BCL2-positive FL and 
DLBCL, in Burkitt lymphoma, mediastinal large B-cell lymphoma and MALT 
lymphoma, whereas in healthy B-cell development the expression of AID is 
highly regulated and restricted to GC B-cells. The constitutive expression of 
AID may contribute to NHL formation. To analyse whether AID expression is 
associated with the pathogenesis of BCL2-negative FL, we measured AID 
mRNA expression in eight cases of BCL2-negative FL and compared the results  
 
 
 
to those of seven BCL2-positive FL. AID mRNA was expressed at various 
levels in both BCL2-positive and negative FL, but did not reach the level 
detected in normal GC cells. AID expression of FL may reflect the GC origin of 
the tumour cells as has also been suggested previously by the presence of 
somatic mutations of IgVH genes of the tumour cells. This is consistent with 
previous findings showing coincidence of AID expression with ongoing type of 
SHM of the Ig genes in FL. The fact that we did not find significant differences 
in AID mRNA and protein expression levels between BCL2-positive and 
negative FL adds further support to the concept that these two variants of FL 
belong to the same entity.  
SHM and AID activity have also been implicated in the alterations of 
proto-oncogenes such as PIM-1, PAX-5, RhoH and c-MYC, which are involved 
in the pathogenesis of different types of B-cell lymphomas. The rates of ASHM 
we found in FL without BCL2 rearrangement and expression were lower than 
previously reported in DLBCL, but similar to those published by others and 
found by us for BCL2-positive FL, suggesting that both BCL2-positive and 
negative FL are targeted by a low frequency of ASHM, and BCL2 expression 
does not influence the incidence of ASHM in FL. 
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VI. CONCLUSIONS 
 
 Our findings suggest that FL may develop even without the 
involvement of the BCL2 gene, although, BCL2 protein overexpression 
is considered to be a critical pathogenic event in the development of 
FL. 
 
 Our findings demonstrate that follicular lymphomas without BCL2 gene 
rearrangement and expression are associated with ongoing type of 
somatic hypermutation (SHM) of the IgVH genes, low activity of 
aberrant somatic hypermutation and elevated activation-induced 
cytidine deaminase expression. These results are in concordance with 
the results found in the BCL2-positive follicular lymphoma cases.  
 
 These data suggest that BCL2-positive and BCL2-negative FL may 
have different molecular alterations at the starting point of 
lymphomagenesis, but in both cases the GC microenvironment and the 
immunoglobulin receptor complex may provide additional signal(s) 
required for malignant transformation. 
 
 The present data support the hypothesis that BCL2-positive and BCL2-
negative follicular lymphomas (grades 1-3A) represent a homogenous 
group with different initial but several common additional molecular 
pathways which lead to highly similar morphological, 
immunophenotypic and also molecular features. 
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